CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Other languages Charles River Laboratories International, Inc. Deutsche Boerse AG

Equities

RV6

US1598641074

Market Closed - Deutsche Boerse AG Other stock markets 11:37:56 10/05/2024 am IST			5-day change	1st Jan Change
212.9 ^EUR	-2.38%		-0.42%	-0.56%

10/05	JPMorgan Adjusts Price Target on Charles River Laboratories International to $270 From $280	MT
10/05	Jefferies Adjusts Price Target on Charles River Laboratories International to $226 From $235	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Charles River Laboratories International Q1 Non-GAAP Earnings Rise, Revenue Fall; Maintains Full Year 2024 Earnings Guidance	09/05
Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024	09/05
Stocks Down Pre-Bell Ahead of Latest Earnings Results; Asia, Europe Churn	09/05
Charles River Laboratories International, Inc. Revises Financial Guidance for 2024	09/05
China trade heats up, UK rates in view	09/05
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids	25/04
Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission	24/04
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing	16/04
Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology	11/04
Charles River Laboratories, Axovia Therapeutics Collaborate on Developing Rare Disease Gene Therapies	09/04
Charles River Laboratories International, Inc. Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics	09/04
Charles River Laboratories Signs Plasmid DNA Manufacturing Deal With Ship of Theseus	04/04
Charles River Laboratories International, Inc. and Ship of Theseus Announces Good Manufacturing Practice Plasmid DNA Contract Development and Manufacturing Organization Agreement	04/04
Charles River Laboratories International, Inc Receives a Shareholder Proposal from People for the Ethical Treatment of Animals	29/03
Charles River Laboratories International, Inc. Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine	21/03
Charles River Laboratories International, Navega Therapeutics Partner for Production of AAV-Based Gene Therapy	14/03
Charles River Laboratories International, Inc. and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration	14/03
Charles River Laboratories International Insider Sold Shares Worth $959,545, According to a Recent SEC Filing	05/03
DURECT Corporation and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for Alzet® Product Line in U.S. and Canada	04/03
Charles River Laboratories International Insider Sold Shares Worth $1,268,500, According to a Recent SEC Filing	02/03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Charles River Laboratories International, Inc. Deutsche Boerse AG

Equities

RV6

US1598641074

Other languages

Filters